Rigel Pharmaceuticals, Inc. (RIGL)
NASDAQ: RIGL · Real-Time Price · USD
47.37
-1.30 (-2.67%)
Sep 8, 2026, 4:00 PM EDT - Market closed
Rigel Pharmaceuticals Employees
As of December 31, 2025, Rigel Pharmaceuticals had 174 total employees, including 172 full-time and 2 part-time employees. The number of employees increased by 10 or 6.10% compared to the previous year.
Employees
174
Change (1Y)
10
Growth (1Y)
6.10%
Revenue / Employee
$1,590,718
Profits / Employee
$1,850,052
Market Cap
884.87M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 174 | 10 | 6.10% | 172 | 2 |
| Dec 31, 2024 | 164 | 17 | 11.56% | 162 | 2 |
| Dec 31, 2023 | 147 | -8 | -5.16% | 147 | 0 |
| Dec 31, 2022 | 155 | -10 | -6.06% | 155 | 0 |
| Dec 31, 2021 | 165 | -4 | -2.37% | 165 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Ardelyx | 489 |
| Olema Pharmaceuticals | 150 |
| Cybin | 100 |
| Annexon | 92 |
| Theravance Biopharma | 90 |
| Silence Therapeutics | 88 |
| Aclaris Therapeutics | 73 |
| Crescent Biopharma | 69 |
RIGL News
- 7 days ago - Rigel to Participate in Upcoming September Investor Conferences - PRNewsWire
- 23 days ago - Rigel Pharmaceuticals price target raised to $49 from $40 at Piper Sandler - TheFly
- 23 days ago - Rigel Pharmaceuticals’ Veppanu available for metastatic breast cancer - TheFly
- 23 days ago - Rigel Pharmaceuticals price target raised to $85 from $57 at H.C. Wainwright - TheFly
- 27 days ago - Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer - PRNewsWire
- 4 weeks ago - Rigel Pharmaceuticals price target raised to $83 from $81 at Citi - TheFly
- 5 weeks ago - Rigel Pharmaceuticals raises FY26 revenue view to $285M-$295M from $275M-$290M - TheFly
- 5 weeks ago - Rigel Pharmaceuticals Earnings Call Transcript: Q2 2026 - Transcripts